TheraRadar
Clinical-Stage Companies / Scynexis

Scynexis

Pre-Approval PRO BETA
🔴

Stale Activity

No new clinical trials started in 2+ years. Activity may be declining or company may be focusing on existing programs. Last trial started: 7/12/2023

17
Total Trials
7
Phase 3
5
Phase 2
0
Recruiting
160
Score

Pipeline by Phase

Phase 3
7
Phase 2
5
Phase 1
5

Therapeutic Focus

Candidiasis, Invasive Candidemia Vulvovaginal Candidiasis Candida Vulvovaginitis Invasive Pulmonary Aspergillosis

Clinical Trials (17)

NCT05178862 Phase 3 TERMINATED

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Started: 8/3/2022

NCT03059992 Phase 3 COMPLETED

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

Started: 4/1/2017

NCT05399641 Phase 3 COMPLETED

Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

Started: 5/1/2022

NCT03363841 Phase 3 COMPLETED

Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)

Started: 11/15/2017

NCT04029116 Phase 3 COMPLETED

Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)

Started: 10/21/2019

NCT03734991 Phase 3 COMPLETED

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)

Started: 1/4/2019

NCT03987620 Phase 3 COMPLETED

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis

Started: 6/7/2019

NCT03672292 Phase 2 TERMINATED

Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis

Started: 1/22/2019

NCT02244606 Phase 2 COMPLETED

Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis

Started: 9/1/2014

NCT03253094 Phase 2 COMPLETED

Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis

Started: 8/1/2017

NCT02679456 Phase 2 COMPLETED

Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis

Started: 11/1/2015

NCT01265511 Phase 2 COMPLETED

Study of SCY-635, Pegasys and Copegus in Hepatitis C

Started: 11/1/2010

NCT06954493 Phase 1 COMPLETED

Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp

Started: 7/12/2023

NCT05668429 Phase 1 COMPLETED

ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects

Started: 12/14/2022

NCT04092725 Phase 1 COMPLETED

Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects

Started: 9/9/2019

NCT04092751 Phase 1 COMPLETED

Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects

Started: 11/22/2019

NCT04307082 Phase 1 COMPLETED

ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects

Started: 12/5/2019

Drug Candidates

SCY-078 Fluconazole Echinocandin Ibrexafungerp Voriconazole Micafungin Fluconazole Tablet IBREXAFUNGERP Placebo oral tablet Placebo
Activity Status: Stale
Last Trial Started: 7/12/2023
Last Trial Ended: 12/16/2025
Trials (12 months): 0
Completed Trials: 15
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.